- Home
- Products
- Customized FluoroAb™
- ERBB2
- Anti-ERBB2 MAb (Clone 17)-iFluor® 460 Succinimidyl Ester
Anti-ERBB2 MAb (Clone 17)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8122)
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB2
- Alternative Names
- ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; neuro/glioblastoma derived oncogene homolog (avian); NGL; v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); receptor tyrosine-prEGF receptor family members to form a heterodimer; stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways; such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported; with the most common allele; Ile654/Ile655; shown he
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Humanized Anti-ERBB2 Antibody (Clone 17)
- Species Reactivity
- Human
- Name
- iFluor® 460 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 468/493
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS8122. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-1114 | Anti-ERBB2 (Pertuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1113 | Anti-ERBB2 (Pertuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1116 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1110 | Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1112 | Anti-ERBB2 (Pertuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Lintuzumab-iFluor 555 (CAT#: ADC-FL-492)
- Anti-DLL3 MAb (Clone 4)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS6443)
- Anti-CD38 MAb (Clone 5)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS1123)
- Anti-TNFRSF17 MAb (Clone 27)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2488)
- Anti-CD3E MAb (Clone 17)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10362)
- Anti-CA9 MAb (Clone 5)-iFluor® 450 Succinimidyl Ester (CAT#: WJY0-LS6984)
- Anti-ENPP3 MAb (Clone 1)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS479)
- Anti-EGFR MAb (Clone 5)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14049)
- Fanolesomab-iFluor 546 (CAT#: ADC-FL-1553)
- Anti-EGFR MAb (Clone 10)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS4957)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.